Levobupivacaine is an enantiomer of racemic bupivacaine with a safe pharmacological profile. We present a review of levobupivacaine and its current clinical use in regional anaesthesia and pain management. The pharmacokinetic and pharmacodynamic profile of levobupivacaine is discussed and a qualitative review of studies involving levobupivacaine for regional anaesthesia is presented. Comparisons of levobupivacaine with other local anaesthetic agents as well as studies looking at different doses of levobupivacaine are overviewed.
Introduction
Reports of significant mortality and morbidity after regional anaesthesia utilising the local anaesthetic agent bupivacaine in the late 1970s 1 led to the development of enantiomers of racemic bupivacaine with safer pharmacological profiles. The levorotatory or S(−) stereoisomers known as levobupivacaine and ropivacaine have been available since the late 1990s, 2 and have been associated with less central nervous system and cardiovascular toxicity than their dextrorotatory or R(+) counterpart dextrobupivicaine.
3
This review appraises the pharmacological profile of levobupivacaine and its current clinical use in regional anaesthesia and pain management.
Structure
The three commonly used long-acting local anaesthetic solutions bupivacaine, levobupivacaine and ropivacaine are all structurally related (Table 1) . Bupivacaine is a racemic mixture of S(−) and R(+) enantiomers; levobupivacaine is the S(−) (or levo) enantiomer of bupivacaine, and ropivicaine is an S(−) enantiomer that resembles bupivacaine structurally. Bupivacaine is an amino-amide local anaesthetic that belongs to the n-alkyl-substituted pipecoloxylidide family. Its molecular structure contains a chiral centre on a piperidine ring, with a butyl group on the amine portion of the pipecoloxylidide. 4 It is this 4-carbon-chain butyl group that confers its high lipid solubility. Levobupivacaine, having the same molecular structure as bupivacaine, is also highly lipidsoluble, whilst ropivacaine possesses a propyl group on the amine portion of pipecoloxylidide, and this 3-carbon side-chain substitution causes the molecule to be much less lipophilic than that of bupivacaine or levobupivacaine. 5 The pharmacokinetic differences of levobupivaciane, bupivacaine and ropivocaine are well described [6] [7] [8] [9] and summarised in Table 1 .
Pharmacodynamics

Mechanism of action
Levobupivacaine, like other local anaesthetic agents, is thought to exert its effects on neuronal membranes by reversibly binding sodium ion channels, thereby preventing voltage-dependent increases in sodium ion conductance, ultimately inhibiting the initiation and propagation of action potentials in neuronal cells. Levobupivacaine has been likened to other local anaesthetic agents in being able to block smalldiameter neuronal fibres more readily than large fibres, explaining the blocking of nociception before other sensory modalities. However, the situation remains complex, as the absolute sensitivity of nerve cells to local anaesthetic agents is not merely related to the diameter of the nerves, but also to the degree of myelination and differences in the population of sodium channels. Levobupivacaine has a pKa of 8.09 (equal to that of bupivacaine) and a volume of distribution of 67 litres. It is .97% plasma protein bound at concentrations between 0.1 and 1 mcg/mL. 9 Its high plasma protein binding and high lipid solubility seem to explain its prolonged duration of action, whilst its pKa (higher than that of lignocaine) explains its slower onset of action, as less of the drug will be unionised at physiological pH. High lipid solubility has also been correlated with the potency of local anaesthetics.
Adverse reactions
Levobupivacaine was developed following concerns of serious central nervous system (CNS) and cardiovascular adverse reactions (including mortality) after inadvertent systemic spread of racemic bupivacaine. [10] [11] [12] Central nervous system manifestations range from paraesthesia and mild tremors to seizures and generalised CNS depression, 13, 14 whilst cardiovascular reactions include negative inotropy, conduction disturbance (QRS complex widening and dysrhythmias), and death caused by pump failure and/or malignant dysrhythmias. [15] [16] [17] It is thought that the cardiotoxic effects of bupivacaine arise as a result of both direct cardiac action (eg, blocking of sodium and potassium channels) and indirect stimulation of the CNS. [18] [19] [20] In studying the toxicity of bupivacaine, the significance of chirality became evident. 20 The disparate properties of enantiomers of a chiral compound, though previously known, required the advances in the manufacturing of single enantiomers to allow exploitation of these differences. A ranking of toxicity is thus achievable based on chirality, with an isolated heart model showing that the two pure enantiomers (ropivacaine and levobupivacaine) have less myocardial depressant properties than racemic bupivacaine, with the pure R(+) bupivacaine enantiomer being the most cardiotoxic.
Animal studies have also suggested that levobupivacaine has a higher safety margin than racemic bupivacaine, 20, [22] [23] [24] with approximately 30% to 40% less systemic toxicity than bupivacaine on a mg:mg basis. 15, 23 One study demonstrated the mean fatal dose (± standard deviation) of intravenous levobupivacaine in sheep (277 ± 51 mg) to be significantly greater than that of racemic bupivacaine (156 ± 31 mg). 24 However, there are limited human studies investigating the adverse reactions to intravenous administration of levobupivacaine. One randomized double-blind crossover study 25 involved the administration of 10 mg/min of either levobupivacaine hydrochloride or (racemic) bupivacaine hydrochloride intravenously into healthy male volunteers (n = 14), to a mean dose of 56.1 mg and 47.9 mg respectively. Subjects were monitored for CNS and cardiovascular symptoms. There were no significant differences in the mean and median threshold doses for either drug with regard to their subjective CNS tolerability. While there were no statistically significant differences between PR interval and QT interval (QT c ) prolongation, levobupivacaine was associated with ; P = 0.001), acceleration index (−0.09 vs. −0.20; P = 0.011), and ejection fraction (−2.5% vs. −4.3%; P = 0.024). On the other hand, when a similarly structured randomized double-blinded crossover study 26 was performed comparing IV administration of levobupivaciane and ropivacaine in healthy volunteers (n = 13), CNS and cardiovascular effects were similar, suggesting a similar toxicity profile of these two pure enantiomeric drugs. Concerns regarding the vasoactive effects of these three long-acting local anaesthetic drugs on maternal-fetal circulation and the degree of placental transfer have not been conclusively resolved, with no clear benefit of one drug over the other in obstetric situations. A study comparing these three local anaesthetic agents administered as a two-step intravenous infusion in 30 near-term pregnant ewes 27 showed that maternal blood pressure, central venous and intra-amniotic pressures, acid-base status and uterine blood flow were unaffected, with no significant differences in maternal serum, fetal serum, fetal tissue concentrations, and tissue:serum concentration ratios.
Relative potencies
There is a hypothesis that lipid solubility is the primary determinant of intrinsic anaesthetic potency. Theoretically, the more lipophilic a molecule is, the easier it enters neuronal axon membranes, thus requiring fewer molecules to achieve the desired effect. Consistent with this, levobupivacaine and racemic bupivacaine (which have similar lipid solubility) have been demonstrated to be 50% more potent than ropivacaine (which has lower lipid solubility) in inhibiting tetrodoxin-resistant sodium channels. 28 The situation is more complex than this, however, with evidence that despite having similar intracellular concentrations (and thus overcoming lipophilicity as an issue), a difference in the potency of phasic block can still be demonstrated.
29
In humans, it is more difficult to compare relative potencies, as often the doses used in a clinical setting are at the top of the dose-response curves. Instead, the "minimum local anaesthetic concentration" (MLAC) is most often used as an alternative, which is defined as the median effective analgesic concentration in the first stage of labour, and was developed to determine equipotent analgesic concentrations of local anaesthetics, to compare motor effects and to evaluate the relative toxicity during labour. 30 The term MLAD (median local anaesthetic dose) or ED50 has been employed for a similar concept applied to intrathecal administration of local anaesthetic.
In a randomized, double-blind, sequential allocation study (n = 60), the efficacy of 20 mL of epidural levobupivacaine or bupivacaine was measured using a visual analogue pain score. The MLAC of levobupivacaine was 0.083% w/v and the MLAC of bupivacaine was 0.081% w/v. The mean potency ratio of levobupivacaine:bupivacaine was 0.98. 31 In another study looking at the MLAD of intrathecal bupivacaine, levobupivacaine and ropivacaine in an obstetric population (n = 89), the relative analgesic mean potency ratios were found to be 0.65 for ropivacaine:bupivacaine, 0.80 for ropivacaine:levobupivacaine, and 0.81 for levobupivacaine:bupivacaine. 32 However, MLAC/ MLAD studies are not uniform, and can sometimes have contrasting results. While there are multiple studies that have reported ropivacaine to be about 20 to 30% less potent than levobupivacaine, [32] [33] [34] [35] [36] there are also studies that show no significant differences between the two drugs.
37, 38 When comparing levobupivacaine with bupivacaine and ropivacaine, however, it is important to realize that the commercial preparation of levobupivaciane labels the percentage solution by weight of the active base only, whilst the other two local anaesthetic agents record percentage solution according to the hydrochloride salt. 39 This means that the concentration of levobupivacaine as the hydrochloride salt should be 13% higher than that reported by the commercial preparation of the base form-ie, 5 mg/mL (0.5%) levobupivacaine base is actually 5.63 mg/mL (0.563%) levobupivacaine hydrochloride. 40 Whilst the sensory MLAC potency ratio of levobupivacaine to bupivacaine is 0.98, if a correction is made for molar concentrations this falls to 0.87 (neither value being different from unity).
31
Additionally, whilst levobupivacaine has been shown to have slightly lower motor-blocking capacity than bupivacaine with a levobupivacaine:bupivacaine potency ratio for epidural motor blockade of 0.87 (95% CI, 0.77-0.98), 41 this may be entirely explained by differences in molarity.
Despite the confusion, clinical studies suggest that a linear trend of potency exists between the three local anaesthetics and should be considered as bupivacaine . levobupivacaine . ropivacaine.
Pharmacokinetics Absorption
Human studies have demonstrated that although the volume of distribution of levobupivacaine at steady state was significantly lower than that of dextrobupivacaine, its decreased toxicity was likely attributed to its increased protein-binding affinity, resulting in a smaller fraction of unbound drug, which causes a higher clearance and shorter elimination half-life.
42
Levobupivacaine has a non-linear binding pattern, binding to both albumin (a low-affinity, high-capacity binding site) and α 1 -acid glycoprotein (a high-affinity, low-capacity binding site) in plasma. 43 At lower concentrations it is mainly bound to albumin; however, in higher concentrations there is a much greater affinity for α 1 -acid glycoprotein. 44 In vitro studies estimate levobupivacaine 0.1-1.0 µg/mL to be .97% bound to plasma proteins, 9 whilst a study following IV administration to healthy volunteers indicated a steady-state volume of distribution of 54 L.
45
Drug absorption and systemic disposition are affected by the route of administration and the vascularity of the tissue at the site of administration.
9
Following IV administration of levobupivacaine at 10 mg/min to a mean dose of 56.1 mg, the mean maximum plasma concentration at the end of the infusion or shortly thereafter was 2.62 µg/mL. 25 The rate of systemic absorption of levobupivacaine is increased when administered into tissue sites with high vascularity. 46 When administered as a scalp block, levobupivacaine was rapidly absorbed, requiring only a mean of 12 minutes to reach maximal plasma concentration. It has also been noted that when the same dose of levobupivacaine was administered for a brachial plexus block, the mean duration to reach peak plasma concentration was 33% shorter when administered to both deep and superficial tissue than to superficial tissue alone.
47
The absorption of levobupivacaine following epidural administration is biphasic, 45, 48 with one study showing the means of fraction absorbed and the half-life of the fast absorption process were 0.22 and 5.2 (minutes) respectively, whilst the values for the slow absorption process were 0.84 and 386 (minutes) respectively. 45 Compared to younger patients, there have been reports of decreased fraction absorbed and shorter absorption half-life of levobupivacaine in older patients; however, studies so far have failed to produce statistically significant results. 48 Nonetheless, the possibility of changes in pharmacokinetics with increasing age remains. Studies evaluating the absorption kinetics of levobupivacaine are presented in Table 2 .
49-53
Metabolism and elimination
Following the IV administration of 30 mg racemic bupivacaine to healthy volunteers, the S(−) enantiomer 
45
Metabolism of levobupivacaine occurs almost exclusively in the liver. [54] [55] [56] by N-dealkylation, primarily to pipcolyloxylidine. N-desbutyl bupivacaine and 4 hydroxy bupivacaine are also formed. 57 This extensive process occurs through the liver cytochrome p450 enzyme system, and mainly involves the CYP3A4 and the CYP1A2 isoforms. 9, 58 It is therefore unsurprising that the mean total body clearance was noted to be slower (0.492 L/min) in a population of liver transplant patients following intercostal blockade. 59 Once metabolised, it is excreted in urine (71% within 48 hours) and faeces (24%).
9
While it has been proposed that there could be potential interactions between levobupivacaine and cytochrome p450 inhibitors (eg, ketoconzaole acting on CYP3A4 and methylxanthines acting on CYP1A2), there have not been any clinical studies performed to confirm this. 9 Furthermore, studies have indicated that the main metabolites formed (ie, pipcolyloxylidine, N-desbutyl bupivacaine and 4 hydroxy bupivacaine) only constitute up to 5% of the dose administered, and therefore drug interactions caused purely by inhibition of certain cytochrome p450 isomers seem unlikely.
58,60-62
Efficacy
To determine the efficacy of levobupivacaine in clinical practice, a restricted qualitative review of studies involving levobupivacaine for regional anaesthesia was performed. This review was based on Englishlanguage studies conducted on adult subjects which compared levobupivacaine with other local anaesthetic agents; studies looking at different doses of levobupivacaine; and studies related to the use of additives with levobupivacaine. Specifically, this review did not include studies focusing on derivation of potency, regional technique, comparisons with non-regional techniques (including the use of saline as control), comparisons amongst different regional techniques, or studies where the conclusions were not clear from the abstract. The findings of this review are summarised in Tables 1-7 and focus on direction in change and main findings regarding analgesia, sensory and motor block.
One of the problems with the literature is that the differences related to the use of levobupivacaine base as opposed to the hydrochloric salt were not clearly taken into account in most of these studies. As a result, caution must be taken with interpreting small differences in alleged " equipotent" dosing of levobupivacaine, bupivacaine and ropivacaine, which may be explained by differences in molarity. This is particularly true of comparisons between levobupivacaine and bupivacaine where the absence of appropriate molarity comparisons increases the apparent potency of levobupivacaine. It is prudent to bear in mind that in general, comparisons are between levobupivacaine base against ropivacaine or bupivacaine hydrochloride.
Levobupivacaine in Spinal Anaesthesia/Analgesia-Obstetric Anaesthesia
Intrathecal levobupivacaine has been compared with ropivacaine in several obstetric studies for Caesarean section. When 6.6 mg of levobupivacaine was compared with a purported "equipotent" dose of 10 mg ropivacaine (both with sufentanil at 3.3 mcg), analgesic supplementation was still required with the ropivacaine cohort. 63 On the other hand, an intrathecal dose of 8 mg levobupivacaine was just as efficacious as 12 mg ropivacaine (both with 2.5 mcg sufentanil added). 64 The differences may be explained by dosing closer to ED95 rather than ED50.
Studies looking at the same mg dose of levobupivacaine and bupivacaine (with opioids) for Caesarean section consistently show a discrepancy with regards to motor block; either less overall motor block 63, 65 or shorter duration of motor block. 64, 65 However, in one of these studies, 64 there were also more failures of anaesthesia with levobupivacaine and shorter duration of analgesia with levobupivacaine, lending support for slight non-equivalence, with bupivacaine being more potent.
Analgesia
The use of levobupivacaine has been studied as an intrathecal dose for use in early labour. There seems to be similar efficacy with ropivacaine when both are used at 2.5 mg or 3.0 mg, 35, 66 which is surprising, given the reported discrepancies in MLAD/ED50. 32, 35 However, the ED95 (albeit with sufentanil 1.5 mcg) of both agents has been reported as being very similar (5.0 mg for levobupivacaine and 4.8 mg for ropivacaine, 67 which may explain the similarities in efficacy. Of course, the volume of anaesthesia utilised doses of anaesthetic agent in the latter study looking at ED95 were much higher than those used to establish equivalence with the studies of Sia et al 35 and Lim et al, 66 but the strict definition of efficacy established in the ED95 study may explain the difference.
When intrathecal levobupivacaine has been compared to an equivalent amount of bupivacaine (both 2.5 mg) for labour analgesia, motor block seems to be less prominent in the levobupivacaine group.
66,68
This may come at a cost of shorter duration of analgesia with levobupivacaine, 66 though this was not apparent in the study by Vercauteren et al, 68 perhaps because they used sufentanil 0.75 mcg/mL together with adrenaline 1.25 mcg/mL in both groups.
Levobupivacaine in Spinal Anaesthesia-Non-Obstetric
Intrathecal levobupivacaine has been used to establish surgical anaesthesia in a range of non-obstetric settings. For perianal surgery, a remarkably low dose of hyperbaric levobupivacaine at 1.5 mg (to achieve a "perianal block" only to S4) was just as successful as a conventional dose of hyperbaric levobupivacaine at 6 mg (for a saddle block), but was associated with earlier time to ambulate, void and readiness for discharge. 69 A low dose of hypobaric 4 mg levobupivacaine with 10 mcg fentanyl for knee arthroscopy was associated with quicker ambulation and higher percentage able to bypass the post-anaesthesia recovery unit when compared with 5 mg with 10 mcg fentanyl, 70 though 3 mg resulted in an unacceptably high failure rate. The advantage of using .7.5 mg of plain levobupivacaine (without any opioid) has been questioned, as there was no difference in time to discharge or first analgesic use or failure rate, even though it shortened the time for readiness to surgery. 71 One study has examined the effect of baricity on levobupivacaine, comparing hyperbaric to isobaric 13.5 mg levobupivacaine at 3 mL for urological surgery 72 : it was found that hyperbaric solutions reduced time to onset of surgical block, time to maximum block, time to regression to L1, time to motor block and duration of motor block, without compromising analgesic effects.
In comparison to ropivacaine at ostensibly equipotent doses in the context of knee arthroscopy, 5 mg hyperbaric levobupivacaine for unilateral block led to similar surgical anaesthesia results and time to discharge as 7.5 mg hyperbaric ropivacaine 73 ; isobaric levobupivacaine at 10 mg has also been shown to be similar to isobaric ropivacaine 15 mg. 74 Consistent with the above studies, equivalent mg dosing of isobaric levobupivacaine and ropivacaine for lower abdominal surgery found levobupivacaine to be more potent, with longer duration of motor and sensory block.
75
When isobaric levobupivacaine has been compared to isobaric bupivacaine, several orthopaedic studies suggest clinical equivalence 76,77 at 15 mg and 17.5 mg. Levobupivacaine may be more haemodynamically stable requiring less ephedrine and atropine than bupivacaine when used at 15 mg for lower abdominal surgery. 75 When used for transurethral surgery (together with fentanyl), levobupivacaine 7.5 mg was found to have longer time for onset of maximum motor block than bupivacaine 7.5 mg, 78, 79 whilst having a longer duration of sensory block. 78 However, in one of these studies, 79 the peak sensory block took longer to achieve and was lower in height (and thus associated with less hypotension and nausea) than bupivacaine, presumably because of the use of plain rather than heavy anaesthetic agents. Interestingly, when plain levobupivacaine was compared with hyperbaric bupivacaine at higher doses (12.5 mg each) for transurethral surgery, there was no difference in motor or sensory block.
80
Studies comparing levobupivacaine and lignocaine for intrathecal anaesthesia are difficult to compare given their vastly different pharmacodynamics. Nevertheless, it is of interest that the motor block resolution with 10 mg of intrathecal levobupivacaine was just as quick as 60 mg intrathecal lignocaine for knee arthroscopy, despite having a more prolonged sensory block and time to voiding. 74 Also, 3 mg of intrathecal levobupivacaine with 10 mcg fentanyl diluted to 3 mL produced similar results (such as onset time of anaesthesia, time to ambulate postoperatively and time for home discharge) as 10 mg lignocaine with 10 mcg fentanyl diluted to 3 mL for laparoscopic sterilization.
81 A statistically significant shorter regression of anaesthesia was demonstrated with lignocaine than levobupivacaine in this study, but this is unlikely to be clinically significant (93 minutes vs. 105 minutes).
The effects of opioids on intrathecal levobupivacaine include a sparing effect. The addition of 25 mcg of fentanyl allowed a reduction of levobupivacaine Onset of anaesthesia from 7.5 mg to 5.0 to achieve the same block height relevant for inguinal hernia surgery, but with shorter regression of block, time to ambulate, time to micturate and time to discharge. 82 Similarly, the addition of 15 mcg of fentanyl to levobupivacaine for transurethral surgery allowed a reduction in levobupivacaine from 12.5 mg to 11 mg, which resulted in shorter time of motor block and a lower sensory block height.
83
Levobupivacaine in Epidural Anaesthesia/Analgesia-Obstetric Anaesthesia
There appears to be no benefit to the addition of opioids when topping up a low-dose epidural infusion for Caesarean section, if opioids have been running in the low-dose mixture already.
84 Doing so was found to increase the incidence of nausea and vomiting without altering onset time of anaesthesia or rate of analgesic supplementation.
For the creation of surgical anaesthesia appropriate for Caesarean section, levobupivacaine has been compared to ropivacaine, 85 bupivacaine [86] [87] [88] and with lignocaine mixtures. 89, 90 Levobupivacaine 0.5% was found to be similar in onset and quality of analgesia when compared to ropivacaine 0.75%.
87
Levobupivacaine seems to behave similarly to bupivacaine at equivalent mg doses [86] [87] [88] ; however, lowerlimb motor block appeared to be longer, though less intense with levobupivacaine in one study. 88 The increase in duration of motor block with levobupivacaine is surprising given that the epidural MLAC for motor block show that levobupivacaine is slightly less potent than bupivacaine.
33,41
When levobupivacaine 0.5% was compared to 1.8%-2% lignocaine mixtures, levobupivacaine performed less well, either requiring more analgesia supplement, 89 or taking longer to achieve appropriate blockade. 90 On the other hand, this finding was not borne out in the study by Sia et al, 35 who found similar results between levobupivacaine 0.5% and 2% mixtures. However, this may have been because of the higher amounts of local anaesthetic used in the infusions for labour analgesia before "topping up" for Caesarean section.
Analgesia
Low concentrations of levobupivacaine (around 0.05%) with sufentanil have been used for labour analgesia, but have been found to be less effective for analgesia than higher concentrations (around 0.1% or higher) also with sufentanil. 91 The effect of clonidine (at 2 mcg/mL) on 0.0625% levobupivacaine combined with sufentanil 0.25 mcg/mL using a patient-controlled epidural analgesia technique was an improvement in analgesia, but with a reduction in blood pressure, albeit still in the normal range.
92
The studies comparing levobupivacaine and ropivacaine for labour analgesia have been confusing. No difference was found when comparing supposedly equipotent concentrations of these agents with sufentanil 0.5 mcg/mL (levobupivacaine 0.0625% against 0.1% ropivacaine). 93 However, when Atienzar et al 94 studied "equipotent" doses of 0.125% levobupivacaine against 0.2% ropivacaine (both with fentanyl 1 mcg/mL), worse pain scores were recorded with levobupivacaine. When a bolus of these same concentrations (ie, 0.125% levobupivacaine and 0.2% ropivacaine) was given and then continued at a rate of 10 mL/hr, both at "non-equipotent" concentrations of 0.1%, analgesia was not different. 95 This, when considered with the study by Atienzar et al, 94 implies that the continuous infusion of equivalent concentrations of levobupivacaine and ropivacaine is important for maintaining equivalent analgesia. Interestingly, two studies show equivalence between levobupivacaine and ropivacaine when used at the same mg dose.
96,97
Additionally, in an admittedly underpowered study to thoroughly examine levobupivacaine, comparison with ropivacaine showed no difference in adequate analgesia, though motor block was less with levobupivacaine.
98
Whilst one study examining levobupivacaine and bupivacaine at equivalent doses for labour analgesia appears to show similar efficacy for analgesia (with fentanyl), 95 other studies suggest inferior analgesia 93, 94, 99 and less motor block 94, 98 with levobupivacaine.
Levobupivacaine in Epidural Anaesthesia/Analgesia-Non-Obstetric Anaesthesia
Successful surgical anaesthesia has been achieved using levobupivacaine at a median dose of about 15 mL at 0.5% concentration for lower limb procedures. This seems equivalent to the corresponding volume of ropivacaine 0.75% 100 or bupivacaine 0.5% 101 in terms of onset and offset of sensory and motor block. Nevertheless, differences have been observed at these doses. In a study involving hip surgery, 0.5% levobupivacaine followed by a PCEA infusion using 0.125% levobupivacaine was associated with requiring more intraoperative anaesthesia than ropivacaine 0.75% followed by a 0.2% solution for PCEA or bupivacaine 0.5% bolus followed by 0.125% solution for PCEA.
102
Also, 0.5% levobupivacaine at 1.2 mL/dermatome had less motor block than bupivacaine 0.5% at the same volume (both given with fentanyl).
103
These doses are based on an assumption of potency ratio of 1.5:1 for levobupivacaine with regards to ropivacaine, and near equipotency between levobupivacaine and bupivacaine, which has been established by the obstetric literature. At higher concentrations, this ratio may not be optimal. For example, in lower abdominal surgery, epidural anaesthesia using 0.75% levobupivacaine was associated with a more prolonged sensory block and a delayed onset of motor block 104 than 0.75% bupivacaine. Despite this, time to onset of surgical anaesthesia and peak block height were similar.
This potency ratio has also been recently challenged in a recent study by Casati et al 101 who demonstrated equivalent time to onset of surgical anaesthesia conditions and time to recovery of pinprick with similar total mg amounts of levobupivacaine, ropivacaine and bupivacaine, all at 0.5%, suggesting equipotent sensory block potential. However, motor block was greater with bupivacaine and levobupivacaine than ropivacaine immediately after block completion, implying a discrepancy between potencies with regards to motor and sensory block.
Analgesia
In studies looking at dosing of levobupivacaine for analgesia, higher concentrations are associated with better analgesia. Murdoch et al 105 reported superior analgesia with levobupivacaine 0.25% solution run at 6 mL/hr for orthopaedic procedures compared to a 0.125% solution, without an increase in motor block. The superiority of analgesia with higher concentrations is true even when opioids are added to the solution. A weak solution of 0.0625% together with sufentanil 1 mg/mL run at 5 mL/hr (ie, 3.125 mg/hr of levobupivacaine) for thoracotomy pain was found to be less efficacious than a 0.125% levobupivacaine solution together with sufentanil 1 mg/mL run at 5 mL/hr (6.25 mg/hr of levobupivacaine). 106 However, when the dosing was altered to a constant mg/hr regime (ie, running a higher volume for a lower concentration of levobupivacaine), [107] [108] [109] no difference in analgesia quality was observed. On the other hand, a higher volume has been associated with a higher upper sensory block height, hypotension and nausea.
109
When opioids are added to epidural solutions of levobupivacaine, analgesic supplementation is delayed, and lower pain scores at rest and activity are achieved.
110,111
The effect of epinephrine on epidural analgesia for spine surgery was to reduce serum concentrations, but with no difference in sensory block.
112
In analgesic studies, levobupivacaine 0.125% was found to be similar or equivalent to ropivacaine 0.2%, 101, 102, 113 but inferior to ropivacaine 0.165%,
114
implying a necessity to ensure equipotency when comparing different local anaesthetic agents. However, the relative potency of ropivacaine to levobupivacaine in the non-obstetric scenario has not been fully characterised. In fact, one study found no difference in analgesia quality with ropivacaine 0.125% and levobupivacaine 0.125% when using a PCEA technique.
115
In comparing levobupivacaine with racemic bupivacaine, 0.125% levobupivacaine may require more total drug amount than the same concentration of bupivacaine.
102
Levobupivacaine for Peripheral Nerve Blocks Anaesthesia
Even though the MLAC for levobupivacaine has been demonstrated to be different depending on the block performed, 116 for ease of comparison, studies will be grouped based on the local anaesthetic agents used.
In studies comparing the effects of different concentrations of levobupivacaine, an ultra-low dose of levobupivacaine (36 mg in 36 mL) for axillary block was unexpectedly found to be just as efficacious as a higher dose (72 mg in 36 mL).
117 This is in contrast to other studies showing slower onset time, shorter regression of motor block in sciatic nerve block, 118 and less complete sensory block and shorter duration with 3-in-1 blocks 119 with lower concentrations. In terms of adjuvants to levobupivacaine for peripheral blocks, intravenous clonidine prolonged postoperative analgesia in psoas compartment block, whilst perineural infusion of clonidine did not. 120 This may be because of non-responder behaviour of clonidine with perineural blocks. 121 Dexmedetomidine given perineurally, however, shortened onset of sensory and motor block whilst prolonging the duration of sensory and motor block as well. However, it was also associated with more hypotension and bradycardia.
122
When comparing levobupivacaine with ropivacaine, studies comparing near-equipotent or equipotent concentrations show the need for more rescue sedation 123 , delayed sensory onset 123, 124 , longer duration of sensory block 125 , delayed onset of motor block 125, 126 , less motor block 127 , and slightly shorter motor block duration 128 when using levobupivacaine in a variety of blocks. Studies comparing equivalent mg doses of levobupivacaine and ropivacaine, on the other hand, also show a variety of responses including superior post-op analgesia, 129 no difference 130, 131 or less complete sensory and motor block with levobupivacaine. 132 These disparate results may indicate different responses depending on the location of the block performed and the regimen utilised.
Levobupivacaine has been compared with bupivacaine and found to behave similarly in terms of sensory and motor block in most studies.
119,133-135
Nevertheless, these findings are not consistent, with motor block shown to be less with levobupivacaine in some studies 127, 132 and sensory block also shown to be less complete.
132
There has only been one small study examining the potential use of levobupivacaine for intravenous anaesthesia of the upper limb. 136 In eight volunteers, 40 mL of 0.125% levobupivacaine was compared against 40 mL of 0.5% lignocaine. Unsurprisingly, levobupivacaine was found to have slower onset of block and longer duration of block.
Analgesia
There are a number of studies examining peripheral nerve block infusions using a patientcontrolled analgesic technique involving perineural levobupivacaine. 130, [137] [138] [139] Three of these studies demonstrated a greater potency of levobupivacaine compared to ropivacaine. In one of these studies, the volume of 0.25% levobupivacaine utilised for patientcontrolled interscalene analgesia was similar to that of 0.4% ropivacaine but not 0.25% ropivacaine 137 ; in another study, there was no difference in the volumes utilised for patient-controlled femoral catheters when using 0.125% levobupivacaine or 0.2% ropivacaine 138 ; and yet another study suggested that 0.125% levobupivacaine might be even more potent than 0.2% ropivacaine in patient-controlled interscalene analgesia, given the reduction in volume utilised in the levobupivacaine group. 130 The only other study comparing levobupivacaine and other local anaesthetics in peripheral nerve block infusion is difficult to interpret, given that the infusion regimes at different concentrations were administered after an equivalent mg dose of each agent had been given as a bolus.
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Levobupivacaine for Ocular Blocks
When comparing allegedly equipotent doses of levobupivacaine and ropivacaine for peribulbar blocks (0.5% levobupivacaine vs. 0.75% ropivacaine 140 or 0.75% levobupivacaine vs. 1% ropivacaine,
141
) levobupivacaine appeared to have better akinesia and longer duration of block. In contrast, "equipotent" doses of levobupivacaine and bupivacaine (either at 0.5% each 142 or 0.75% each 143, 144 ) produced very similar results, although less pain on injection was noted with levobupivacaine used for retrobulbar block.
142
Levobupivacaine has also been compared with lignocaine; unsurprisingly, levobupivacaine was found to have a longer duration of motor and sensory block (using 0.5% solution
) and a slightly slower onset of block (using 0.75% solution
145
) than lignocaine 2%. On the other hand, when levobupivacaine 0.75% was compared to a mixture of 2% lignocaine and 0.5% bupivacaine, there was no difference in verbal pain score or ocular movement scores over time.
141 A lignocaine 2% plus levobupivacaine 0.5% mix has been compared with 4% articaine in sub-Tenon's anaesthesia and found to have a slower onset and inferior akinesia than the articaine block 146 ; however, the differences in potencies do not allow valid comparisons.
Levobupivacaine for Local Infiltration, Topical and Intra-Articular Use
For intra-articular use, 0.5% levobupivacaine has been shown to be more efficacious than 0.25% levobupivacaine or 1% lignocaine with 5 mcg/mL of epinephrine. 147 Comparisons between levobupivacaine and other short acting agents (viz mepivacaine 148 and lignocaine [149] [150] [151] for local infiltration after removal of impacted 3rd molars, 148,149 nasal surgery 150 or ocular topical use, 151 consistently show superior analgesia when using levobupivacaine.
In comparisons between levobupivacaine and ropivacaine for local infiltration, levobupivacaine appears to perform better, even at less than " equipotent" concentrations. Longer duration of analgesia and less consumption of analgesic agents were demonstrated with 0.5% levobupivacaine compared to 1% ropivacaine for laparoscopic cholecystectomy, 152 and 0.15% levobupivacaine was associated with less pain at 4 and 24 hours than 0.375% ropivacaine. 153 Nevertheless, when used for ocular topical blocks, no difference was found between 0.75% levobupivacaine and 1% ropivacaine.
151
In contrast, traditionally quoted "equipotent" concentrations of levobupivacaine appear to be equivalent to bupivacaine.
144,155
Place in Therapy
Studies in a variety of clinical settings and methods of administration have generally shown that levobupivacaine, ropivacaine and bupivacaine have similar anaesthetic and analgesic effects at equipotent doses. It was noted, however, that intrathecal levobupivacaine tended to have a longer time to onset of adequate motor blockade. There are contrasting reports of the duration and efficacy of sensory and motor blockade following levobupivacaine compared to bupivacaine, with some studies reporting that both drugs behaved similarly, whilst others reported decreased sensory/motor blockade with levobupivacaine. Levobupivacaine was also shown to provide better anaesthesia/analgesia than ropivacaine when used for local infiltration.
Whilst providing comparable anaesthetic and analgesic properties to the more commonly used bupivacaine, levobupivacaine has been shown to be associated with less cardiovascular and CNS toxicity, and a greater safety margin in both animal studies and healthy human volunteers. These properties suggest that levobupivacaine would be a useful alternative to bupivacaine in clinical scenarios where toxicity is perceived to be a higher risk, such as use of higher doses or concentrations (eg, peripheral limb blocks), administration into highly vascular areas (eg, scalp blocks), or in patient populations perceived to potentially be more susceptible to toxicity (eg, paediatric or geriatric populations).
Conclusion
In conclusion, levobupivacaine is a long-acting amino-amide local anaesthetic that is closely related to bupivacaine in structure, and has similar anaesthetic and analgesic properties. In clinical scenarios and patient populations where toxicity is potentially a higher risk, levobupivacaine should be considered as an alternative to racemic bupivacaine due to its safer side-effect profile.
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